^
BIOMARKER:

No biomarker

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
News
Twitter
Trials
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A2
PMLive - 4 days - (New A2)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 6 days - (New A1)
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1 week - (New A2)
No biomarker
Melanoma
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 1 week - (New A1)
No biomarker
T Cell Non-Hodgkin Lymphoma
sugemalimab
Sensitive
:
B
CStone Pharma Press Release - 1 week - (New B)
No biomarker
Soft Tissue Sarcoma
envafolimab
Sensitive
:
B
Tracon Pharmaceuticals Press Release - 1 week - (New B)
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
Lancet Oncol - 2 weeks - (New B)
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive
:
A1
FDA - 2 weeks - (New A1)
No biomarker
Triple Negative Breast Cancer
XMT-1660
Sensitive
:
B
Mersana Therapeutics Press Release - 2 weeks - (New B)
No biomarker
Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A1
Lancet Oncol - 3 weeks - (New B)
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Esophageal Cancer
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
niraparib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
fluorouracil topical
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive
:
A1
No biomarker
Multiple Myeloma
carfilzomib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A1